- Home
- SOCA vs CDXS Comparison
SOCA vs CDXS Comparison
Compare SOCA & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOCA
- CDXS
- Stock Information
- Founded
- SOCA 2025
- CDXS 2002
- Country
- SOCA United States
- CDXS United States
- Employees
- SOCA N/A
- CDXS N/A
- Industry
- SOCA
- CDXS Major Chemicals
- Sector
- SOCA
- CDXS Industrials
- Exchange
- SOCA Nasdaq
- CDXS Nasdaq
- Market Cap
- SOCA 235.0M
- CDXS 216.6M
- IPO Year
- SOCA 2025
- CDXS 2010
- Fundamental
- Price
- SOCA $10.14
- CDXS $1.67
- Analyst Decision
- SOCA
- CDXS Buy
- Analyst Count
- SOCA 0
- CDXS 1
- Target Price
- SOCA N/A
- CDXS $11.00
- AVG Volume (30 Days)
- SOCA 24.1K
- CDXS 1.3M
- Earning Date
- SOCA 01-01-0001
- CDXS 11-06-2025
- Dividend Yield
- SOCA N/A
- CDXS N/A
- EPS Growth
- SOCA N/A
- CDXS N/A
- EPS
- SOCA N/A
- CDXS N/A
- Revenue
- SOCA N/A
- CDXS $52,932,000.00
- Revenue This Year
- SOCA N/A
- CDXS $12.88
- Revenue Next Year
- SOCA N/A
- CDXS $21.64
- P/E Ratio
- SOCA N/A
- CDXS N/A
- Revenue Growth
- SOCA N/A
- CDXS N/A
- 52 Week Low
- SOCA $9.94
- CDXS $1.59
- 52 Week High
- SOCA $10.15
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- SOCA N/A
- CDXS 28.17
- Support Level
- SOCA N/A
- CDXS $1.61
- Resistance Level
- SOCA N/A
- CDXS $2.01
- Average True Range (ATR)
- SOCA 0.00
- CDXS 0.16
- MACD
- SOCA 0.00
- CDXS -0.07
- Stochastic Oscillator
- SOCA 0.00
- CDXS 4.39
About SOCA Solarius Capital Acquisition Corp. Class A Ordinary Share
Solarius Capital Acquisition Corp is a blank check company.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.